Loading patent…
AssigneeTianjin Medical University General Hospital
InventorCHUNSHENG KANG
Estimating the term…
The present disclosure relates to the field of biotechnology, and in particular, to a composite formulation and the use thereof for preparing a drug for treating a tumor. The effective components of the composite formulation of the present disclosure at least comprise a compound having a structural formula shown in Formula I and an EZH2 inhibitor. In terms of the clinical application for tumours, the present disclosure finds that a low dose of the compound having the structural formula shown in Formula I can enhance the therapeutic effects of the EZH2 inhibitor DZNEP and, when used in combination, can reduce the dosage of the EZH2 inhibitor DZNEP by ⅘ whilst ensuring pharmaceutical effectiveness, being an effective combination therapeutic solution.
The use of a compound with a structural formula as shown in Formula I in combination with an EZH2 inhibitor in the preparation of a drug for treating a tumor,
A composite formulation, wherein effective components of the composite formulation at least comprise a compound having a structural formula of Formula I and an EZH2 inhibitor:
The use of a compound with a structural formula of Formula I, wherein the use is selected from one or more of the following:
A method for treating a tumor, comprising the following operation:
A method for treating a tumor, comprising the following operation:
A method for inhibiting tumor proliferation, tumor invasion and tumor metastasis, comprising the following operation:
A method for inhibiting tumor proliferation, tumor invasion and tumor metastasis, comprising the following operation:
A method for treating a tumor, comprising the following operation:
A method for treating a tumor, comprising the following operation:
Dependencies are inferred from the claim text.